Gilead Sciences
29 декабря 2017, 22:43

Market Looks Well Poised for 2018: 5 Solid Stocks to Buy

If the government ably channelizes the policies and implements pro-investors and pro-corporate reforms, Wall Street would continue to be ruled by bulls.

29 декабря 2017, 19:39

15 of the Best Mergers & Acquisitions of 2017

As 2018 fast approaches, we can???t help but look back on the past 12 months. Even though M&A activity was relatively quiet in 2017 compared to past years, the deals that were announced this year were major, and revolved around some of the biggest consumer and technology names. Here are 15 of the best mergers and acquisitions of the year.

29 декабря 2017, 15:56

Intercept (ICPT) Stock Loses Sheen in 2017: What Lies Ahead?

Intercept (ICPT) had a tough time in 2017 after news of death were out related to lead drug's Ocaliva's dosing. We do not expect a phenomenal revival in 2018 either.

29 декабря 2017, 15:42

Celgene (CELG) in Troubled Waters in '17: What Does 2018 Hold?

Celgene's (CELG) stock has been under pressure due to pipeline setbacks. We expect an acquisition in the offing to bolster its portfolio.

Выбор редакции
29 декабря 2017, 15:00

Why Gilead Sciences Stock Should Be Avoided in 2018

Gilead's foray into the adoptive cell-therapy space doesn't bode well for its prospects next year.

28 декабря 2017, 16:23

The Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, Sangamo Therapeutics, AnaptysBio and Sino Biopharmaceutical

The Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, Sangamo Therapeutics, AnaptysBio and Sino Biopharmaceutical

28 декабря 2017, 16:07

5 of the Best-Performing Biotech Stocks of 2017

With 2017 coming to an end, it is time to take a look at the performance of the biotech sector and some of the best-performing biotech stocks including XOMA (XOMA).

27 декабря 2017, 17:48

4 Biotech Stocks Ready to Crush the Market in 2018

The biotech sector has performed well in 2017 and we expect the momentum to continue in 2018 driven by new drug approvals. Here, we list stocks which might be worth adding to your biotech portfolio for 2018.

22 декабря 2017, 18:13

Build a Christmas Tree with Top-Ranked Stocks

As Christmas tree symbolizes good tidings, let's build a similar tree for stock-loving investors that could rake in big gains in 2018.

21 декабря 2017, 18:41

GOP Passes Landmark Tax Bill: Best & Worst for Stocks

While miners, energy, retailers, tech, banks and pharma are expected to enjoy the biggest gains from the tax package, health insurers and hospitals are poised to lose

20 декабря 2017, 16:34

3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2018

Immuno-oncology was a key focus area in 2017 - will it remain so in 2018 as companies like Juno (JUNO) progress with their pipelines?

Выбор редакции
16 декабря 2017, 00:28

CAR T Stocks in Focus with ASH 2017 Meet: GILD, JUNO & More

The CAR-T therapy space has been in spotlight since Aug 2017 and the recent ASH meeting had further put focus on the same.

15 декабря 2017, 22:05

Cancer Space Update: Roche, Pfizer & Regeneron Make Data Presentations

Several presentations at the annual meeting of the American Society of Hematology grab headlines in the cancer space.

13 декабря 2017, 15:38

Biotech Stock Roundup: ASH Data in Focus, Gilead to Buy Cell Design Labs

The annual meeting of the American Society of Hematology was the key highlight this week with several companies like bluebird (BLUE) presenting data on their investigational treatments.

Выбор редакции
13 декабря 2017, 12:47

Борьба с болезнями крови: пять победителей и один проигравший

  • 0

В сфере лечения заболеваний крови много инноваций. Американский Forbes описал самые примечательные

13 декабря 2017, 01:52

Juno Reports Additional Data on CAR-T Therapy, Shares Drop

Juno (JUNO) releases additional results from the ongoing phase I study of its chimeric antigen receptor T-cell (CAR-T) therapy candidate, JCAR017.

12 декабря 2017, 17:55

Bluebird's Shares Jump on Strong Data for CAR-T Therapy

bluebird (BIRD) announced updated results from the ongoing phase I study of its chimeric antigen receptor T-cell (CAR-T) therapy candidate- bb2121.

12 декабря 2017, 02:09

Gilead (GILD) Posts Updated Data on CAR-T Therapy Yescarta

Gilead (GILD) announced follow-up data from a phase II study, on its CAR-T therapy, Yescarta for treatment of refractory large B-cell lymphoma.